Corrigendum to ‘ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents’ [Gynecologic Oncology 107 (2007) 505–512]1 (Ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents (2007) 107(3) (505–512), (S0090825807006270), (10.1016/j.ygyno.2007.08.007));Ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents

Gynecologic Oncology

Volumn 107, Issue 3, 2007, Pages 505-512

  Chen, Yan ^a,b,c   Qian, Haili ^a   Wang, Haijuan ^a   Zhang, Xueyan ^a   Fu, Ming ^a   Liang, Xiao ^a   Ma, Yan ^b   Zhan, Qimin ^a   Lin, Chen ^a   Xiang, Yang ^b  

^a CANCER HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c NORTH CHINA COAL MEDICAL COLLEGE   (China)

Author keywords

Chemosensitivity; Choriocarcinoma; Drug resistance; Gene therapy; PUMA

Indexed keywords

CASPASE 3; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; P53 UPREGULATED MODULATOR OF APOPTOSIS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHEMOSENSITIZATION; CHORIOCARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 36348986653     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2020.08.007     Document Type: Erratum

References (27)

1. Yu J., Zhang L., Hwang P.M., et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7 (2001) 673-682
2. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7 (2001) 683-694
3. Kim H., Rafiuddin-Shah M., Tu H.C., et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8 (2006) 1348-1358
4. Yu J., Wang Z., Kinzler K.W., et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 100 (2003) 1931-1936
5. Yu J., Yue W., Wu B., et al. PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12 (2006) 2928-2936
6. Wang H., Qian H., Yu J., et al. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther 5 (2006) 380-385
7. Ludescher C., Thaler J., Drach D., et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 82 (1992) 161-168
8. Solazzo M., Fantappie O., Lasagna N., et al. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res 312 (2006) 4070-4078
9. Bold R.J., Termuhlen P.M., and McConkey D.J. Apoptosis, cancer and cancer therapy. Surg Oncol 6 (1997) 133-142
10. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat 9 (2006) 19-25
11. Soussi T., and Jonveaux P. p53 gene alterations in human hematological malignancies: a review. Nouv Rev Fr Hematol 33 (1991) 477-480
12. Lane D.P. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harbor Symp Quant Biol 70 (2005) 489-497
13. Zinkel S., Gross A., and Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13 (2006) 1351-1359
14. Lahm A., Paradisi A., Green D.R., et al. Death fold domain interaction in apoptosis. Cell Death Differ 10 (2003) 10-12
15. Ming L., Wang P., Bank A., et al. PUMA dissociates Bax and Bcl-X(L) to induce apoptosis in colon cancer cells. J Biol Chem 281 (2006) 16034-16042
16. Vegran F., Boidot R., Oudin C., et al. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 12 (2006) 5794-5800
17. Haidacher S., Blaschitz A., Desoye G., et al. Immunohistochemical evidence of p53 protein in human placenta and choriocarcinoma cell lines. Hum Reprod 10 (1995) 983-988
18. Aboagye-Mathiesen G., Zdravkovic M., Toth F.D., et al. Altered expression of the tumor suppressor/oncoprotein p53 in SV40 Tag-transformed human placental trophoblast and malignant trophoblast cell lines. Early Pregnancy 2 (1996) 102-112
19. Yaginuma Y., Yamashita T., Takuma N., et al. Analysis of the p53 gene in human choriocarcinoma cell lines. Br J Cancer 71 (1995) 9-12
20. Ito H., Kanzawa T., Miyoshi T., et al. Efficacy of PUMA for malignant glioma cells regardless of the p53 status. Hum Gene Ther 16 (2005) 685-698
21. Karst A.M., Dai D.L., Martinka M., et al. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 24 (2005) 1111-1116
22. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13 (2006) 1859-1876
23. Tainton K.M., Smyth M.J., Jackson J.T., et al. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11 (2004) 1028-1037
24. Ruefli A.A., Tainton K.M., Darcy P.K., et al. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9 (2002) 1266-1272
25. de Kant E., Heide I., Thiede C., et al. MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol 122 (1996) 671-675
26. Chipuk J.E., Bouchier-Hayes L., and Kuwana T. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
27. Middelburg R., de Haas R.R., and Dekker H. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 11 (2005) 1863-1869